Loading...
Market
How many additional regulatory approvals will Elevidy receive by end of 2024?
4
Resolution / Starting Odds
None • 33%
1-3 • 33%
More than 3 • 33%
Regulatory announcements from health authorities in other countries and Sarepta's press releases
Story
Sarepta's Elevidy Receives Full FDA Approval for DMD Gene Therapy, Stock Target Set at $200
Jun 30, 2024, 02:16 PM
Sarepta Therapeutics ($SRPT) has received full FDA approval for its gene therapy for ambulatory patients with Duchenne muscular dystrophy (DMD) and accelerated approval for non-ambulatory patients, as detailed in Elevidy's FDA label. This approval is expected to drive significant revenue growth for the company in the coming quarters. BMO Capital has set a conservative target price of $200 for Sarepta's stock, citing no meaningful competition in the near future. Despite this positive outlook, some investors are skeptical, noting disappointment within the DMD community regarding the therapy and Peter Mark's decision, as well as concerns about the empty capsid ratio in AAV technologies.
View original story
Similar markets
Less than 5 • 33%
5 to 10 • 34%
More than 10 • 33%
0 new indications • 33%
1 new indication • 33%
2 or more new indications • 34%
Less than 5,000 • 25%
5,000 - 10,000 • 25%
10,000 - 15,000 • 25%
More than 15,000 • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
Less than 100 • 33%
100 to 500 • 34%
More than 500 • 33%
